Abstract Familial Alzheimer's disease (FAD) has been shown to be associated with three distinct point mutations within the same codon of the amyloid precursor protein (APP) gene. The mutation identified in the Indiana kindred is a G-+T transversion at the first position of the codon for amino acid 717, resulting in a substitution of phenylalanine for valine in the APP protein. Screening of persons at risk for the APP Phe-717 mutation using a variation of the polymerase chain reaction identified nine positives among 34 tested. In addition, DNA from 145 FAD subjects were tested for the three known APP 717 mutations.
(J7 Med Genet 1993;30:476-8)
Alzheimer's disease, a form of amyloidosis with deposition localised to the central nervous system, is characterised by a progressive dementia. Both sporadic and hereditary forms, with autosomal dominant inheritance, show the characteristic neuropathological findings of senile plaques in the cerebral cortex, neurofibrillary tangles, and congophilic angiopathy of the leptomeningeal vessels. The amyloid forming protein found in fibrils isolated from the blood vessels and senile plaques has been identified as a 39 to 43 (fig 2) .
Results
The detection method used for screening at risk subjects in this study, which we have termed polymerase chain reaction-induced mutation restriction analysis (PCR-IMRA), was initially tested for accuracy and reliability using DNA from patients known to be heterozygous for the APP Phe-717 mutation by direct sequencing. Once the technique had been shown to detect reproducibly the mutant allele in all tested positive controls, it was used to screen an additional 17 members of the Indiana FAD kindred (34 total). Of those tested, a total of nine subjects heterozygous for the Phe-717 mutation were identified. Further screening was conducted on 123 DNA samples obtained from the Alzheimer's Disease Research Centers' National Cell Bank and 25 samples from Duke University. None of these showed the presence of the Phe-717 allele. In addition, 100 unrelated, non-AD controls were tested by PCR-IMRA, as reported previously.4 None of the 200 control alleles screened was positive for the APP Phe-717 mutation.
The 123 samples from the Alzheimer's Disease Cell Bank and all 34 members of the Indiana FAD kindred were also screened for the APP Ile-717 mutation, using conventional RFLP analysis, and the APP Gly-717 mutation, using an additional PCR-IMRA test. One patient from the Alzheimer's Disease Cell Bank was found to be heterozygous for the Ile-717 mutation, while the remainder showed neither mutation (data summarised in the table).
The 25 samples from Duke University were tested for the APP Ile-717 mutation by RFLP analysis. Two samples were heterozygous for the APP Ile-717 allele. Direct sequencing of exon 17 of the APP gene was used to determine that none was positive for the APP Gly-717 allele.
Summary of APP screening results. Number of patients screened for each mutation is indicated, with the number of positive results in parentheses. *Denotes members of original Duke University APP Ile-717 kindred, as described in the text. All positive results indicated represent subjects heterozygous for the mutant allele. 
